Clifton GTT, Hale D, Vreeland TJ, Hickerson AT, et al. Results of a randomized phase IIb trial of nelipepimut-S + trastuzumab vs trastuzumab to prevent recurrences in high-risk HER2 low-expressing breast cancer patients. Clin Cancer Res 2020 Feb 18. pii: 1078-0432.CCR-19-2741.
PMID: 32071118